Revolution Medicines Sees Unusually Large Options Volume (NASDAQ:RVMD)

Revolution Medicines, Inc. (NASDAQ:RVMD) was the recipient of unusually large options trading activity on Tuesday. Stock investors purchased 8,752 call options on the company. This represents an increase of 22% compared to the typical volume of 7,156 call options.

Revolution Medicines Stock Up 7.9%

NASDAQ RVMD opened at $147.01 on Wednesday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 7.14 and a current ratio of 7.14. The firm has a 50-day simple moving average of $99.92 and a 200 day simple moving average of $84.28. Revolution Medicines has a twelve month low of $34.00 and a twelve month high of $148.00. The stock has a market cap of $29.13 billion, a PE ratio of -24.87 and a beta of 1.01.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same quarter last year, the company posted ($1.12) EPS. On average, research analysts forecast that Revolution Medicines will post -3.49 EPS for the current year.

Key Stories Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Positive Phase 3 pancreatic cancer data showing improved survival is driving the rally; this outcome supports regulatory filings and commercialization prospects. RVMD Stock Rallies 41% on Positive Phase III Pancreatic Cancer Data
• Positive Sentiment: Major media and industry outlets report the trial success and survival benefit, corroborating the clinical significance and increasing investor confidence. Revolution Medicines’ experimental cancer pill helps improve survival
• Positive Sentiment: Broad financial press coverage highlights the late-stage win and market reaction, which can attract additional investor attention and liquidity. Pancreatic cancer drug daraxonrasib succeeds in late-stage trial
• Neutral Sentiment: Unusually large call-option buying was observed, suggesting some investors are speculatively leveraging the news; this can magnify volatility but does not change fundamentals by itself.
• Neutral Sentiment: Wedbush reaffirmed an “outperform” rating, which supports the bullish narrative but is not a new upgrade. Benzinga report
• Neutral Sentiment: Analysts and commentators note the data “wows” Wall Street but caution that additional catalysts (regulatory timeline, commercialization plans) will determine sustained upside. PDAC Data Wows Wall Street – Jury’s Out On Further Upside
• Negative Sentiment: Revolution announced proposed public offerings of $750M of common stock and $250M of convertible senior notes (plus underwriter options), which could dilute existing shareholders and pressure the stock once executed. Proposed offerings of common stock and convertible senior notes

Analyst Upgrades and Downgrades

A number of research firms have weighed in on RVMD. Wedbush reissued an “outperform” rating on shares of Revolution Medicines in a research report on Tuesday. Evercore reissued an “outperform” rating on shares of Revolution Medicines in a research report on Tuesday. Truist Financial raised shares of Revolution Medicines to a “strong-buy” rating in a research report on Wednesday, March 25th. Benchmark reissued an “overweight” rating on shares of Revolution Medicines in a research report on Tuesday, February 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Revolution Medicines in a research report on Thursday, January 22nd. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Revolution Medicines presently has an average rating of “Buy” and an average target price of $78.94.

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, insider Xiaolin Wang sold 2,010 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $199,954.80. Following the completion of the transaction, the insider owned 116,063 shares of the company’s stock, valued at $11,545,947.24. The trade was a 1.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Stephen Michael Kelsey sold 4,302 shares of the business’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $427,962.96. Following the transaction, the insider directly owned 295,398 shares of the company’s stock, valued at approximately $29,386,193.04. This represents a 1.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 64,592 shares of company stock valued at $6,488,732 in the last three months. 8.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Revolution Medicines

Several hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Revolution Medicines by 6.7% in the fourth quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company’s stock valued at $1,331,739,000 after buying an additional 1,056,792 shares during the period. Farallon Capital Management LLC lifted its stake in shares of Revolution Medicines by 2.1% in the third quarter. Farallon Capital Management LLC now owns 14,625,692 shares of the company’s stock valued at $683,020,000 after buying an additional 300,000 shares during the period. Janus Henderson Group PLC lifted its stake in shares of Revolution Medicines by 8.3% in the fourth quarter. Janus Henderson Group PLC now owns 12,303,502 shares of the company’s stock valued at $980,036,000 after buying an additional 947,448 shares during the period. Baker BROS. Advisors LP lifted its stake in shares of Revolution Medicines by 1.0% in the third quarter. Baker BROS. Advisors LP now owns 9,455,357 shares of the company’s stock valued at $441,565,000 after buying an additional 90,385 shares during the period. Finally, Nextech Invest Ltd. lifted its stake in shares of Revolution Medicines by 20.7% in the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after buying an additional 1,304,347 shares during the period. Institutional investors own 94.34% of the company’s stock.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.